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Abstract 43 
Cytomegalovirus (CMV) infection sometimes causes large expansions of CMV-specific 44 
T-cells, particularly in older people. This is believed to undermine immunity to other 45 
pathogens and to accelerate immunosenescence. While multiple different CMV proteins 46 
are recognized, most publications on age-related T-cell expansions have focused on 47 
dominant target proteins, UL83 or UL123, and the T-cell activation marker, IFN-. We 48 
were concerned that this narrow approach might have skewed our understanding of 49 
CMV-specific immunity at older ages. We have, therefore, widened the scope of 50 
analysis to include in vitro-induced T-cell responses to 19 frequently recognized CMV 51 
proteins in young and older healthy volunteers and a group of oldest old, long-term 52 
survivors (>85 years of age). Polychromatic flow-cytometry was used to analyze T-cell 53 
activation markers (CD107, CD154, IL-2, TNF, IFN-) and memory phenotype (CD27, 54 
CD45RA). The older had on average larger T-cell responses than the young, but, 55 
interestingly, response size differences were relatively smaller when all activation 56 
markers were considered rather than IFN- or TNF alone. The oldest old recognized 57 
more proteins on average than the other groups and had even bigger T-cell responses 58 
than the older with a significantly larger central memory CD4 T-cell component. (191 59 
words)  60 
  61 
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Introduction 62 
T-cells have a central role in containing virus infections and T-cell immunity to CMV has 63 
been repeatedly characterized [1-4]. As aged T-cells die, the thymus gland replenishes 64 
the T-cell pool with fresh, naïve cells, but thymic output is reduced by 90% in 20 year-65 
olds, and by 99% in 70 year-olds, compared to newborns [5].  However T-cell numbers 66 
do not decline significantly as we age because memory T-cell proliferation compensates 67 
the lack of fresh naïve cells. 68 
Cytomegalovirus (CMV) infection is uniquely effective in driving compensatory memory 69 
T-cell proliferation; other herpes viruses have been implicated in this process to a much 70 
lesser degree [6, 7]. Frequent reactivation of latent CMV is thought to repetitively 71 
stimulate the T-cell compartment, driving up its size over time [8]. Very large CMV-72 
specific T-cell responses observed in older people have created the paradigm of CMV-73 
induced T-cell ‘memory inflation’ [9]. Some researchers suspect that these T-cell 74 
expansions undermine immune responsiveness by skewing the T-cell receptor 75 
repertoire towards CMV [2, 10, 11]. However, the studies exploring the relationship 76 
between immunosenescence and the size of the CMV-specific T-cell response in 77 
humans to date have considered a limited number of recognized target proteins. By 78 
focusing on specific proteins or even individual epitopes and single functions (e.g. IFN-79 
) they have created a fragmented picture of CMV specific T-cell immunity in older life 80 
[10-16].  81 
We intended to assess whether CMV infection leads to a large increase of CMV-specific 82 
T-cells in older people by measuring T-cell responsiveness to a wider, more 83 
representative range of proteins than previously studied and also including several 84 
functional response read-outs. We used protein-spanning peptide pools for CMV 85 
antigen-specific stimulation [17-23]. Target protein selection was based on our previous 86 
work showing that the full size of the response to CMV (represented by 213 protein-87 
spanning peptide pools) can be extrapolated from the responses to 19 proteins, 88 
including 6 dominant CD4 and 15 dominant CD8 T-cell targets [24].  89 
The increase of T-cell response size was smaller in the CD8 but larger in the CD4 90 
compartment in older compared to young participants than previously reported. In 91 
addition, our analysis of response breadth and T-cell memory compartments across all 92 
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protein-specific responses provides new insight into the changes that occur in older 93 
people and a potential signature of successful ageing.   94 
95 
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Methods 96 
Ethics statement 97 
This study was approved by the UK National Research Ethics Service (NRES) 98 
(09/H1102/84) and the University of Parma Ethics Committee. Written informed consent 99 
was obtained from all participants. The study was conducted in agreement with the 100 
Declaration of Helsinki. 101 
 102 
Participants 103 
Fifty-five healthy volunteers referred to as ‘young’ (19-35 years, including university 104 
students and staff) and 131 healthy volunteers referred to as ‘older’ (60-85 years, 105 
recruited by general medical practitioners) were recruited in Brighton (UK). Twenty-two 106 
additional individuals, referred to as ‘oldest old’ (85-102 years) with known T-cell 107 
responsiveness to CMV were recruited at Parma University Hospital (Italy) as a 108 
comparison group of particularly advanced age. Exclusion criteria were designed to 109 
select generally healthy young and older individuals but in the oldest old the presence of 110 
cerebrovascular and/or cardiovascular disease (heart failure, TIA, AMI) was accepted, 111 
as this is representative of such an advanced age. Details of all inclusion/exclusion 112 
criteria and demographics for CMV- participants are provided in the online supplement. 113 
Demographics for CMV+ participants are shown in Table 1. Venous blood was collected 114 
in sodium-heparin plasma tubes (BD, Oxford, UK). Only CMV+ individuals (52.6% of the 115 
older and 47.3% of the young participants) were selected for the analysis of CMV-116 
specific T-cell responsiveness. The proportion of Non-White among young participants 117 
ranged from 20-33%, depending on the analysis. There were no statistically significant 118 
differences between White and Non-White British participants with respect to response 119 
size distribution. 120 
 121 
CMV serology 122 
CMV IgG serology (Architect CMV IgG, Abbot, Maidenhead, UK) was performed at the 123 
Brighton and Sussex University Hospital Trust (BSUHT) virology laboratory.  124 
 125 
Peripheral blood mononuclear cell (PBMC) Isolation and activation 126 
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PBMCs were isolated by density gradient centrifugation (Ficoll-Hypaque, PLUS 127 
Healthcare, Buckinghamshire, UK) as described previously [25]. PBMCs were 128 
resuspended at 5x106 cells/mL in complete RPMI (Fisher Scientific, Loughborough, UK) 129 
containing 10% fetal calf serum (Fisher). For each tube 200 μL of PBMC suspension 130 
was incubated with peptide pools dissolved in DMSO (Sigma-Aldrich, Gillingham, UK), 131 
DMSO alone as a negative control, or Staphylococcus enteroxin B (SEB, Sigma) as a 132 
positive control, and Monensin (BD) for 2 hours in a standard incubator (37°C, 133 
humidified 5% CO2 atmosphere) before addition of BFA (Sigma) for the remaining 134 
incubation time of 14 hours.  More details are provided in the online supplement. 135 
 136 
CMV Peptide Pools  137 
Peptides (15 amino acids length, 11 amino acids overlap between adjacent peptides) 138 
spanning the entire amino acid sequence of 19 CMV proteins were prepared by solid-139 
phase synthesis using the same protein sequences as previously published [24]. Quality 140 
control included mass spectroscopy and HPLC. Peptide purity was generally >80%. 141 
One peptide pool per protein was generated (‘Pepmix’, JPT Peptide Technologies, 142 
Berlin, Germany) save for UL48, for which two pools were required. Pools were 143 
arranged in 16 stimulation pools, of which 12 contained one protein (frequent 144 
responses) and 4 contained 2 proteins each (as they elicited less frequent responses) 145 
(Table 2). Freeze-dried pools were stored at -80°C. 146 
 147 
Antibodies and cell staining  148 
We used the following fluorescence-conjugated monoclonal antibodies; anti-CD3-v500, 149 
anti-CD8-Allophyocyanine(APC)-H7, anti-CD27-Phycoerythrine(PE), IL-2-Fluoresceine-150 
iso-thio-cyanate(FITC), TNF-α- Alexa 700, CD107a-APC (all BD Biosciences, Oxford, 151 
UK), anti-CD4-Peridinin chlorophyll(PerCP), anti-IFN- PE-Cy7(Cyanine 7), anti-CD154 152 
Pacific-Blue (BioLegend, Cambridge, UK), anti-CD45RA-ECD (Beckman Coulter, UK) 153 
and Yellow live-dead stain (Invitrogen, Paisley, UK). Cells were stained on the surface 154 
and intracellularly as described previously [25] (see online supplement for details).  155 
 156 
Data analysis and gating strategy 157 
  8 
FlowJo-v9.x software (TreeStar Inc., Ashland, USA) was used for analysis. After 158 
identifying CD4 and CD8 T-cells, individual gates were set on activation marker-positive 159 
events (Supplementary Fig. S1) and then combined using FlowJo’s Boolean gate 160 
function. All subset frequencies were computed based on the frequencies of individual 161 
non-overlapping Boolean subsets after background subtraction. Responses were 162 
considered positive if they were identifiable by at least one activation marker, formed a 163 
visible cluster on inspection, and included ≥ 0.01% (1/10,000 T-cells) of the reference 164 
population. The analysis of target protein recognition profiles and total CMV-specific 165 
responses excluded participants whose responses had not been tested with the 166 
complete set of 19 peptide-pools (e.g. for lack of sufficient material). 167 
 168 
Absolute T-cell counts 169 
Absolute T-cell counts (cells/nL of whole blood) were determined in most, but not all, UK 170 
participants. They  were computed by multiplying the percentage of CD3 T-cells among 171 
white blood cells with the white blood cell count (wbc) obtained with a Sysmex Counter 172 
(Sysmex, UK) (see online supplement for details). 173 
 174 
T-cell polyfunctionality 175 
The polyfunctionality index was calculated as previously described [26] (see online 176 
supplement for details). 177 
 178 
Statistical analysis 179 
SPSS v22 software (IBM, London, UK) was used for statistical analyses. The Chi-180 
square test was used to compare protein recognition between cohorts. Histograms, Q/Q 181 
plots, and the Kolmogorov-Smirnov test were used to determine data distribution. Non-182 
parametric tests (Mann-Whitney) were used to compare groups. T-cell frequencies were 183 
log-transformed where appropriate for normalizing distribution or improving data 184 
presentation. P-values ≤0.05 were considered significant for single endpoints. Multiple 185 
end-point correction (Bonferroni) was applied when appropriate (p≤0.05/n, where n is 186 
the number of endpoints).   187 
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Results 188 
T-cell response size is unrelated to protein recognition frequency 189 
Size and phenotype of T-cell responses to 19 CMV proteins were analyzed in young, 190 
older, and oldest old participants (Table 1). Activated T-cells were quantified using five 191 
simultaneous read-outs, IL-2, IFN-, TNF, CD107a and CD154. As previously reported, 192 
the average size of the T-cell response to a given CMV protein was unrelated to the 193 
proportion of individuals recognizing it (Fig. 1A-B) [24].  194 
 195 
CMV-specific T-cell response breadth is increased in the oldest old 196 
The frequencies of T-cells recognizing specific target proteins were not significantly 197 
different between young and older participants, however, significant differences existed  198 
between the older and oldest old with respect to several proteins (Fig. 2A). The number 199 
of target proteins recognized per individual seemed somewhat bigger in the older 200 
compared to the young participants but this was not statistically significant. However, 201 
the oldest old had significantly broader responses than the older participants (Fig. 2B). 202 
The oldest old were considered examples of exceptional ageing and compared only 203 
with the older whose age was within normal expectation (direct comparisons between 204 
the oldest old and the young did not appear useful). 205 
 206 
The median frequency of CMV-specific TNF-producing CD4 T-cells is 4.9 times 207 
higher in older than young participants 208 
We initially compared responses between young and older participants as this was 209 
considered to reflect average ageing. As a global measure of T-cell responsiveness to 210 
CMV, without bias to selected proteins, we first compared the summed response to the 211 
19 proteins (‘total response’) among CD4 and CD8 T-cells and then the responses to 212 
the two most frequently recognized proteins for CD4 (UL83, UL55) and CD8 T-cells 213 
(UL83, UL123) (Fig. 3). Response size comparisons were based on the combined 214 
readout (cells were considered activated if at least one activation marker was positive), 215 
IFN- alone (the most commonly used T-cell activation marker) or TNF alone. The 216 
difference of the total CD4 T-cell response between the young and the older (Fig. 3A) 217 
was statistically significant only when IFN-or TNF were considered alone, but not 218 
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when the combined read-out was used. In older participants the median of the total CD4 219 
T-cell response was 3.2, 4.5, and 4.9 fold higher than in the young group for the 220 
combined read-out, IFN-, and TNF, respectively. UL83-specific responses were 221 
significantly larger in the older group for each of the read-outs; unlike UL55-specific 222 
responses, which were not significantly different for any read-out. In CD8 T-cells a 223 
similar pattern was observed but increases were generally smaller (Fig. 3B). Medians 224 
for the total CD8 T-cell response were 2.1, 2.3, and 2.3 fold higher in the older than in 225 
the young group for the combined read-out, IFN-, and TNF, respectively. CD8 T-cell 226 
responses to UL83 were also significantly larger in older compared with young 227 
participants (any read-out), but no significant difference was observed with respect to 228 
UL123 (‘IE-1’).  229 
Interestingly, total response size differences (all 19 proteins) between the oldest old and 230 
the older (aged 85-103) were significant for all read-outs for both CD4 and CD8 T-cells 231 
(Fig. 3A-B, left). This might be explained in part by the higher average number of 232 
proteins recognized in the oldest old (Fig. 2B). For both CD4 and CD8 T-cells, UL83-233 
specific responses were also significantly different between these groups for the 234 
combined read-out and IFN- but not TNF. The UL55-specific CD4 T cell response was 235 
significantly higher in the oldest old group using the combined read out. No direct 236 
comparison between oldest old and young participants was made.  237 
 238 
Absolute T-cell counts may conceal the increasing CMV bias of the T-cell 239 
repertoire in the older  240 
The corresponding response size differences in terms of absolute T-cell counts (cells/nL 241 
of blood) between young and older participants were less conspicuous and statistically 242 
significant only for UL83-specific CD4 T-cells (Supplementary Fig. S2A-B). At the 243 
same time a general decline of CD4 and, particularly, CD8 T-cell numbers (statistically 244 
significant) was observed in the older group (Supplementary Fig. S2C-D). Absolute T-245 
cell counts, therefore, underestimated age-related increases in CMV-specific response 246 
dominance revealed by the responding fractions of CD4 or CD8 T-cells (Fig. 3A-B). 247 
Absolute T-cell counts were not available for the oldest old.  248 
 249 
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CMV-specific CD4 T-cells arise predominantly from the TEM compartment in 250 
young and older but from the TCM compartment in the oldest old 251 
The distributions of CMV-specific CD4 and CD8 T-cells among the memory 252 
compartments defined by CD45RA and CD27 expression were evaluated in all 253 
individuals (CD45RA+/CD27+ = ‘naïve’ or TNA; CD45RA-/CD27+ = ‘central memory’ or 254 
TCM; CD45RA-/CD27- = ‘effector memory’ or TEM; CD45RA+/CD27- = ‘revertant’ or 255 
TEMRA) (Supplementary Fig. S3A). This distribution changes subject to age and CMV-256 
status (Supplementary Fig. S3B) [27], and in CMV+ individuals is also related to the 257 
size of CMV-specific T-cell responses [28]. The quantitative contribution of these 258 
compartments to the total CMV-specific T-cell response was determined across all 19 259 
target proteins. In young and older participants, the largest proportion of the CD4 T-cell 260 
response arose from the TEM compartment (Fig. 3C), whereas in CD8 T-cells an equally 261 
large or even larger contribution originated from the TEMRA compartment (particularly in 262 
the older) (Fig. 3D). Surprisingly, in the oldest old the TCM compartment was dominant 263 
among CMV-specific CD4 T-cells, unlike in older participants, where the TEM 264 
compartment was dominant (Fig. 3C). Note that differences between the sizes of 265 
corresponding memory compartments in different age groups in Fig. 3C-D (for example 266 
the CD4 TCM compartment in the older versus the oldest old participants) reflect the 267 
overall response size differences between these groups and show to what extent these 268 
are located in which memory compartments. However, relative changes in the 269 
contributions each memory compartments makes to the whole response are more 270 
easily appreciated when frequencies are normalized, in which case a significant 271 
increase is visible for oldest old versus older participants in the CD4 TCM compartment 272 
and a significant decrease in older compared with young participants in the CD8 TNA 273 
compartment (Supplementary Fig. S4A). T-cell memory compartment distributions 274 
were also expressed in absolute counts (limited to young and older participants) 275 
showing a very similar pattern as when expressed as fractions of CD4 or CD8 T-cells 276 
(supplementary Fig. S4B).  277 
 278 
The entire CD4 and CD8 T-cell memory compartments (irrespective of antigen 279 
specificity) also showed larger central memory components in the oldest old than the 280 
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older but differences were not significant. The most striking difference compared with 281 
CMV-specific T-cells was the much smaller relative size of the TEMRA compartment. In 282 
older participants the TEMRA compartment dominated the CD8 T-cell repertoire whereas 283 
in the oldest old the TEM compartment was dominant (Supplementary Fig. S4C, top 284 
and bottom). 285 
 286 
We finally tested T-cell polyfunctionality across the memory compartments; it was 287 
generally highest in the TEM compartment in CD4 and CD8 T-cells in all three groups, 288 
however, in the oldest old, despite a general decline of polyfunctionality, the CD8 TNA 289 
compartment was more polyfunctional than in older people (Supplementary Fig. 5). 290 
  291 
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Discussion 292 
Our study explored whether the CMV-specific T-cell response is generally inflated in 293 
older people. It provides a more definitive answer than previous work, which has 294 
focused on select antigens, individual peptides/MHC-multimers, and often single 295 
effector read-outs. While CMV-specific T-cell responses were on average larger in older 296 
than in young people, our data provides compelling evidence that the size of such 297 
differences depends strongly on how the comparison is made; be it with respect to 298 
individual proteins, or a range of proteins, be it with respect to single activation markers, 299 
or a combination of activation markers. Response size differences were more 300 
pronounced when the analysis was focused on single effector read-outs (IFN- TNF), 301 
but less striking when all read-outs were considered simultaneously. This demonstrates 302 
that differences in functional profiles between individuals, or groups of individuals, may 303 
appear as differences in response size if single activation markers are used as read-out.  304 
While 2.1-fold and 3.2-fold higher median frequencies of CMV-specific CD8 and CD4 T-305 
cells, respectively, in older compared to young people (considering all T-cell targets and 306 
read-outs) clearly show a considerable age-related response size increase, it remains 307 
unclear if this is enough to significantly undermine immunity in older people. An 308 
increase of CMV-specific pro-inflammatory T-cells, however, might have a more 309 
profound effect on the immune system. When considering TNF-producing T-cells only, 310 
the difference between young and older was ‘only’ 2.3 fold for CD8 T-cells but, 311 
surprisingly, 4.9 fold for CD4 T-cells (a similar pattern was seen for IFN- producing T-312 
cells). It appears, therefore, that the effect of ageing (within normal bounds) on CMV-313 
specific T-cell numbers has been somewhat overestimated with regard to the CD8 but 314 
underestimated with respect to the CD4 compartment. In any case, our work has 315 
clarified that a huge increase in TNF-producing CMV-specific T-cells does indeed occur 316 
in the average CMV+ older person.  317 
Pourgheysari et al. previously reported significant expansions of CMV-specific CD4 T-318 
cells in older people, however, using a CMV lysate for stimulation. Based on TNF 319 
production they found a little more than a doubling in older compared to younger 320 
people, which is less than half the difference found in the present study. This 321 
discrepancy could be explained, first, by the fact that the ‘young’ people examined by 322 
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Pourgheysari were up to 50 years old compared with up to 35 years in our study, and 323 
second, that CMV lysate (made from CMV-infected fibroblasts) does not stimulate T-324 
cells as effectively as protein-spanning peptide pools [24].  325 
 326 
The oldest old represented a group of exceptional, successfully aged people. They 327 
recognized more proteins on average than the older participants (see Fig. 2B) and their 328 
summed responses to all proteins were much larger, irrespective of read-out. Future 329 
research will determine whether increased response breadth contributes to successful 330 
ageing, is a by-product of successful ageing or possibly the result of lifestyle factors 331 
contributing to longevity. Interestingly, the role of UL83 as an unusual protein in regards 332 
to driving CMV-specific T-cell expansions was confirmed by the observation of an even 333 
larger difference in response size between the oldest old and older than between the 334 
older and the young. Whether very large UL83-specific T-cell responses are harmful, 335 
helpful, or maybe neither, remains unclear. Unlike the young and older, who were 336 
predominantly White British, the oldest old were White Italian. Both population samples 337 
belong to the same major ethnicity (Caucasoid), however, the frequencies of some HLA 338 
alleles vary between UK and Italian populations according to the online HLA-allele 339 
database, www.allelefrequencies.net [29]. It may be that HLA-type or other genetic 340 
factors have affected response breadth and/or size somewhat but it is unlikely that they 341 
would explain the full extent of the differences we have observed.  342 
 343 
By quantifying the contribution of the different T-cell memory compartments to the 344 
overall CMV-specific response in a summative way across all 19 target proteins, our 345 
study significantly extends previous reports [10, 28, 30]. This comprehensive evaluation 346 
demonstrated that both in young and older participants the bulk of the CMV-specific T-347 
cell response arises from the TEM compartment in CD4 T-cells, and to a similar extent 348 
from the TEM and TEMRA compartments in CD8 T-cells. In the oldest old ‘survivors’, 349 
however, a large contribution to the CD8 T-cell response size and the largest 350 
contribution to the CD4 T-cell response size originated from the TCM compartment. This 351 
raises the question, does an increase of this compartment occur as a result of 352 
successful ageing or is it a survival advantage during the process of ageing? The latter 353 
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would support the idea that a long-lived TCM pool provides improved protection from 354 
infection as a result of its ability to proliferate upon antigen re-exposure [31]. 355 
Interestingly, it was recently shown that the live attenuated VZV vaccine, Zostavax, 356 
boosts polyfunctional central memory CD4 T-cells in individuals aged 55-65 [32]. It is, 357 
therefore, tempting to speculate that expansion of the TCM compartment both in terms of 358 
CMV-specific T-cells, but also generally, reflects natural boosting by exposure to real 359 
infections. However, this observation and potential consequences for vaccine design 360 
would need to be assessed in future studies.  361 
Importantly, the definition of T-cell memory compartments by CD45RA versus CD27 362 
expression is not precise, e.g. T cells in the naïve compartment would not be expected 363 
to produce IFN- after overnight stimulation, indicating a more advanced phenotype. 364 
Nonetheless these, and similar subset definitions based on two markers (e.g. CD45RA 365 
and CCR7) provide good overall subset discrimination and are widely used in the field 366 
[28, 33]. Interestingly, stem cell memory T-cells (TSCM) are antigen-experienced and, like 367 
naïve cells, express CD45RA and CD27. It is possible, therefore, that the oldest old, 368 
have accumulated CMV-specific TSCM [34] potentially contributing to protection.  369 
Using the same cohorts, we recently reported that polyfunctionality was on the whole 370 
reduced in the oldest old [35], however, we did not examine differences between T-cell 371 
memory subsets. Our current analysis confirmed that polyfunctionality in the oldest old 372 
is generally lower than in older individuals but showed a slight increase of it in CD8 TNA 373 
cells. This agrees with a recent report by others showing increased polyfunctionality 374 
among CD8 TNA (but, interestingly, not TSCM) cells in an older compared to a younger 375 
participant group [36]. Age-wise, their older group was in between our older and oldest 376 
old groups.  377 
Importantly, our present work shows that age-related expansions of the CMV-specific T-378 
cell response can only be fully appreciated if a representative range of proteins and 379 
several functional read-outs are considered in combination, allowing an assessment of 380 
response breadth both in regards to target proteins and functionality. We also previously 381 
demonstrated striking differences between individuals regarding CMV protein 382 
dominance and response hierarchies [37], providing additional reason to use many 383 
target proteins in parallel for this kind of work. In conclusion, our current and previous 384 
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findings combined suggest that a possible ‘signature’ of successful ageing might include 385 
a broad CMV-specific T-cell response with a large central memory component but 386 
overall moderate polyfunctionality (thus avoiding unnecessary ‘collateral’ tissue 387 
damage) [35]. We believe that our work will be useful in informing the design of future 388 
studies in this field. 389 
  390 
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Tables 395 
 396 
Table 1. CMV+ participant demographics 397 
Parameter  ‘young’  ‘older’  ‘oldest old’ 
Total n 26 69 22 
Age range (mean ± STD) 19 – 35 
(23.3±4.2) 
60 – 85 
(69.0±7.5) 
85-103 
(95.9±5.9) 
Females 18 (69 %) 35 (51 %) 16 (73%) 
Males 8 (31 %) 34 (49 %) 6 (27%) 
White (British or Italian) 18 (69%) 69 (100 %) 22 (100%) 
Non-White Britisha 8 (31%) 0 (0%) n.a. 
aNon-white British young adults included 1 Syrian, 2 Indian, 1 Sri-Lankan, 398 
1Bangladeshi, 1 Malaysian, 1 White/Asian and 1 Black African/Asian participants. 399 
 400 
 401 
 402 
  403 
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Table 2: CMV peptide-pools used for stimulation 404 
Protein(s) No. of Peptides 
UL55 224 
UL83 138 
UL86 340 
UL122 120 
UL123 143 
UL99 45 
UL153 67 
UL32 260 
UL28 92 
UL48Aa 281 
UL48Ba 281 
US3 44 
UL151& UL82 219 (82 &137) 
UL94 & US29 197 (84 &113) 
UL103 & 
US32 
103 (60 & 43) 
US24 & UL36 240 (123 &117) 
a UL48 was divided into two pools (UL48A and UL48B), however, results were combined 405 
 406 
  407 
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Figure Legends 408 
 409 
Fig. 1. The frequency of target protein recognition is unrelated to T-cell response 410 
size. PBMC from CMV+ participants were stimulated overnight with 19 CMV protein-411 
derived overlapping peptide-pools. Activated T cells were identified by flow-cytometry. 412 
(A) Bars represent all age groups and indicate the fraction of individuals recognizing 413 
individual proteins with respect to CD4 and CD8 T-cells. Proteins are ordered by 414 
decreasing frequency of recognition. (B) The sizes of CD4 and CD8 T-cell responses 415 
(Log10 transformed fractions) across all age groups are shown for all proteins in the 416 
same order as under (A).  417 
 418 
Fig. 2. The breadth of the CMV-specific T-cell response is not significantly 419 
different between young and older participants but strongly increased in the 420 
oldest old. PBMC from CMV+ participants were stimulated over night with 19 CMV 421 
protein-derived overlapping peptide-pools. Activated T cells were identified by flow-422 
cytometry. (A) A comparison of response breadth between the young (white bars) and 423 
older (grey bars) individuals revealed no significant differences in terms of protein 424 
recognition frequencies (CMV proteins are ordered by decreasing frequency of 425 
recognition in the older group), however, there were several significant differences 426 
between the older and the oldest old (dark grey bars) (Bonferroni multiple end-point 427 
correction, significance threshold set to p=0.003, significant differences indicated by 428 
asterisks). (B) The number of recognized CMV target proteins (between 1 and 15) was 429 
computed separately for CD4 and CD8 T-cells in the young (left) and older (middle), 430 
and oldest old (right), suggesting a mild (non-significant) trend for higher response 431 
counts in older compared to young participants, but showing a significant difference 432 
between older and oldest old. Cross-bars show median and interquartile range. 433 
 434 
Fig. 3. Age-related increases in T-cell response size depend on target protein-435 
specificity and functional response read-out. PBMC from CMV+ participants were 436 
stimulated over night with 19 CMV protein-derived overlapping peptide-pools. Activated 437 
T cells were identified by flow-cytometry. While our study focused on ‘average’ ageing, 438 
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i.e. differences between young and older participants, oldest old participants are shown 439 
as examples of unusually succesful ageing. (A, B) The fractions of all cells displaying at 440 
least one activation marker (‘combined read out’), IFN-, or TNF are shown. Diagrams 441 
show the CMV-specific T-cell response size (log-transformed fractions of CD4 or CD8 442 
T-cells) for all 19 proteins combined (left panels) and the most frequently recognized 443 
CMV proteins in the UK cohort (A) for CD4 T-cells with respect to UL83 (middle) and 444 
UL55 (right), (B) for CD8 T-cells with respect to UL83 (middle) and UL123 (right). 445 
Statistical significance levels are indicated. The main study end-point was the increase 446 
in CMV-specific T-cell response size between young and older people (combined read-447 
out in connection with all 19 proteins); the significance level of p≤0.05 was not adjusted. 448 
(C,D) T-cell memory compartment distributions defined by the expression of CD27 and 449 
CD45RA (CD45RA+/CD27+ = ‘naïve’ or TNA; CD45RA-/CD27+ = ‘central memory’ or 450 
TCM; CD45RA-/CD27- = ‘effector memory’ or TEM; CD45RA+/CD27- = ‘revertant’ or 451 
TEMRA) showed significant differences between young and older participants among 452 
CMV-specific TCM CD4 T-cells and CD8 revertant (TEMRA) T-cells. Compared with older 453 
participants, the oldest old displayed a striking and significant increase of the CD4 454 
central memory (TCM) compartment (Mann-Whitney test, significance threshold set to at 455 
p≤0.0125, Bonferroni correction for 4 end-points). No direct comparison was made 456 
between the young and oldest old participants. Boxplots show minimum, maximum, 457 
median, interquartile range, and outliers (“o”). 458 
459 
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Materials and Methods 24 
 25 
Participants 26 
Inclusion criteria for UK donors: age 20-35 or 60-85 years; exclusion criteria were  27 
known immunodeficiency (including HIV-infection), organ transplantation, use of 28 
immunosuppressive or immune-modulating drugs within the last year (excluding 29 
acetylsalicylic acid ≤ 100mg/day), cancer or treatment for cancer within the previous 5 30 
years, insulin dependent diabetes, moderate or advanced renal failure, liver disease, 31 
endocrine disorders (except corrected thyroid dysfunction), autoimmune disease, 32 
dementia/mental incompetence, alcohol/other drug abuse, acute infection or illness in 33 
the last 4 weeks, raised body temperature (>37.5C).  34 
 35 
Inclusion criteria for Italian volunteers: minimum age 85 years, known CMV 36 
responsiveness; exclusion criteria were  evidence of endocrine (except thyroid 37 
dysfunction), autoimmune and neoplastic diseases, acute infections or illness in the last 38 
2 months, renal or liver failure, and use of immune-modulatory medications (including 39 
steroids, non-steroidal anti-inflammatory agents, acetylsalicylic acid >100mg/day, or 40 
immunosuppressive drugs). 41 
 42 
Peripheral blood mononuclear cell (PBMC) Isolation and activation 43 
Dissolving peptide pools and PBMC stimulation: 44 
Twenty-five μg per peptide of CMV peptide-pools (“PepMix”, JPT Peptide Technologies, 45 
Berlin, Germany) was dissolved in 100 μL of dimethyl-sulfoxide (DMSO, Sigma-Aldrich, 46 
Gillingham, UK). Two μL of peptide solution, 1.5 μL of anti CD107a (BD) and 0.5 μL of 47 
Monensin (BD) were added to 46 μL of complete media and placed in 4.5 mL 48 
polystyrene tubes (BD). After the addition of 200 μL of PBMC suspension the tubes 49 
were incubated at 37°C in a standard incubator with a humidified 5% CO2 atmosphere. 50 
After 2 hours, 1 μL of Brefeldin A (5 μg/ml; Sigma) was carefully added in 249 μL of 51 
complete media and samples were incubated for a further 14 hours. Final 52 
concentrations of peptide were 1 μg/mL per peptide for each pool. Staphylococcus 53 
enteroxin B (SEB) (Sigma) was dissolved in DMSO and used at 1 μg/ml (final 54 
 2 
concentration) as positive stimulation control, 2 μL DMSO alone was added as a 55 
negative control. 56 
 57 
 58 
Absolute T-cell counts: 59 
In order to obtain absolute T-cell counts, 100 μl of fresh whole blood (EDTA-anti-60 
coagulated) was stained with CD45 PerCP and CD3 Qdot605 (all from BioLegend) for 61 
30 min at 4°C, prior to adding 1 ml of FACS lysing solution (BD) and incubating for 10 62 
min according to the manufacturer’s instructions. Then 3 ml of wash buffer were added, 63 
samples were centrifuged, and aquired on an LSR II flow-cytometer (BD).  64 
White blood cells were selected according to CD45 expression on a side scatter versus 65 
CD45 plot. The percentage of CD3 T-cells among white blood cells was determined on 66 
a side scatter versus CD3 plot. The absolute CD3 T-cell count was determined by 67 
multiplying this percentage with the absolute white blood cell count (cells/nL). In order to 68 
determine absolute CD4 and CD8 T-cell counts the absolute CD3 T-cell count (cells/nl) 69 
was multiplied with CD4 and CD8 T-cell percentages.  70 
  71 
 3 
Supplementary Tables: 72 
 73 
Table 1. CMV- participant demographics 74 
Parameter  ‘young’  ‘older’ 
Total number 29 62 
Age range (mean ± STD) 20 – 34 
(25.5±4.7) 
60 – 85 
(72.2±8.2) 
Females 18 (62 %) 28 (45 %) 
Males 11 (38 %) 34 (55 %) 
White (British or other 
Europeana) 
29 (100%) 62 (100 %) 
a Other European: 1 young adult from Greece and 1 young adult from Switzerland.  75 
  76 
 4 
Supplementary Figure Legends 77 
 78 
Supplementary Fig. S1: Gating strategy for T-cell activation markers.  79 
(1) Lymphocytes were gated on an FSC-A versus SSC-A plot. (2) Single cells were 80 
gated on an FSC-H versus FSC-A plot. (3) Dead cells were excluded using a viability 81 
dye in the violet 3 channel. (4) T-cells were first selected on a CD3 versus CD8 plot, 82 
allowing for some CD3 down-regulation on activated CD8+ events (‘CD3_8’). (5) CD3 T-83 
cells were also gated alternatively on a CD3 versus CD4 plot, this time allowing for 84 
some CD3 down-regulation on activated CD4+ events (‘CD3_4’). (6) Both CD3 gates 85 
were then combined (logical ‘OR’), so that the final CD3 T-cell gate included a 86 
maximum of activated CD4 and CD8 T cells. (7)-(11) Subsequently, activated CD8 T-87 
cells were gated with respect to each functional parameter (one by one). The same 88 
process was repeated for activated CD4 T-cells. (12) Phenotypic subsets based on the 89 
expression of CD45RA and CD27 were gated on all CD4 or all CD8 T-cells (including 90 
activated and non-activated) and then combined (logical ‘AND’) with the respective 91 
activation marker gates (or gates derived from these). The numbers/frequencies of 92 
activated CD4 or CD8 T-cells for each combination of phenotypic and functional subsets 93 
were computed subsequently. The positive assay control (SEB) was used to ascertain if 94 
the assay had worked (even if individuals were not responding to CMV-antigens), 95 
whereas the negative assay control (unstimulated) was used to estimate (and subtract) 96 
‘background noise’ for each functional subset (subset by subset). 97 
 98 
Supplementary Fig. S2: Differences between young and older people in terms of 99 
absolute numbers of CMV-specific CD4 and CD8 T-cells are smaller than in terms 100 
of relative numbers. PBMC from CMV+ participants were stimulated over night with 19 101 
CMV protein-derived overlapping peptide-pools. Activated T cells were identified by 102 
flow-cytometry. The presented data is limited to the UK cohort. (A, B) Diagrams show 103 
absolute counts/nL of CD4 and CD8 T-cells displaying at least one activation marker 104 
(combined read out), IFN-γ, or TNF. Responses are shown to the 19 proteins combined 105 
(left panels) and the most frequently recognized CMV proteins in the UK cohort (A) for 106 
CD4 T-cells with respect to UL83 (middle) and UL55 (right), (B) for CD8 T-cells with 107 
 5 
respect to UL83 (middle) (‘pp65’) and UL123 (right) (‘IE-1’). Significant differences at the 108 
p≤0.05 level are indicated. In addition, ‘n.s.’ (not significant) is indicated for those 109 
differences that were significant using relative T-cell counts (frequencies, compare Fig. 110 
3A-B). Note that in order to determine if there is a general increase in CMV-specific T-111 
cell response size between young and older people, the main end-point was the 112 
combined functional read-out (‘at least one marker positive’) in connection with all 19 113 
tested proteins. The significance level was not adjusted for multiple end-points in (A) or 114 
(B). Absolute counts (in cells/nL of blood) of CD4 (C) and CD8 T-cells (D) seem to 115 
diminish in older people. The effect was not significant for CD4 but highly significant for 116 
CD8 T-cells. As a result, in particular for CD8 T-cells, fewer differences between the 117 
age groups were significant compared to when subset sizes were expressed as a 118 
percentage of CD4 or CD8 T-cells (compare Fig. 3A-B). Boxplots show minimum, 119 
maximum, median, interquartile range, and outliers (o). 120 
 121 
Supplementary Fig. S3: CMV-infection significantly affects memory subset 122 
distributions in the young and older groups. The unstimulated control tube for each 123 
participant was used for the analysis of CD4 and CD8 T-cell distributions across the 124 
canonical memory compartments defined by the expression of CD27 and CD45RA 125 
(CD45RA+/CD27+ = ‘naïve’ or TNA; CD45RA-/CD27+ = ‘central memory’ or TCM; 126 
CD45RA-/CD27- = ‘effector memory’ or TEM; CD45RA+/CD27- = ‘revertant’ or TEMRA). 127 
Data for CMV+ and CMV- individuals are shown. (A) CMV infection per se has a major 128 
impact on memory subset distribution in both young and older people as previously 129 
shown by us and others [27]. Dot-plots show the TNA (upper right quadrant), TCM (lower 130 
right quadrant), TEM (lower left quadrant), and TEMRA (upper left quadrant) compartments. 131 
(B) The effect of CMV-infection on the naïve T-cell pool is only significant in older 132 
people. Interestingly, the effect of CMV infection on the TEMRA (CD27-/CD45RA+) 133 
compartment seems to be stronger in CD4 than CD8 T cells. Boxplots show minimum, 134 
maximum, median, interquartile range, and outliers (o).  135 
 136 
 137 
Supplementary Fig. S4: Proportional memory subset distributions of CMV-138 
 6 
specific T-cells are reflected by distributions in absolute counts but differ from 139 
those of all T-cells. (A) In analogy with Fig. 3C-D, the distribution of T-cells across the 140 
memory compartments, TNA, TCM, TEM, and TEMRA is shown for each age group. 141 
However, instead of frequencies of CD4 or CD8 T-cells, the diagram shows the 142 
proportions that each subset contributes to the whole response (normalized). (B) In 143 
analogy to Fig. 3C-D, the memory subset distributions of CMV-specific CD4 and CD8 T-144 
cell were analyzed in terms of absolute T-cell counts (limited to the young and older 145 
groups). In each individual and with respect to each CMV-peptide pool, the percentages 146 
of CD4 and CD8 T-cells in the TNA, TCM, TEM, and TEMRA memory compartments were 147 
added up to provide a total response for each memory compartment. These 148 
percentages were multiplied with the absolute CD4 and CD8 T-cell counts in cells/nL. 149 
Differences between the age groups by and large reflect the distributions observed in 150 
relative terms. (C) The unstimulated control tube was used for the analysis of memory 151 
subsets for all T-cells (CMV-specific and non-CMV-specific) in CMV+ people across all 152 
three age groups. Boxplots show minimum, maximum, median, interquartile range, 153 
outliers (o), and extreme values (*).  154 
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